Launched in March 2020 to develop innovative therapeutics with a focus on oncology, AmMax Bio, Inc. (“AmMax”) is a clinical stage company successfully leveraging its expertise in translational and clinical development to build a strong oncology portfolio focused on sizeable market opportunities via licensing and partnerships. The Company’s portfolio, anchored by a novel next generation antibody-drug conjugate (ADC), has the potential to create new standards of care.
AmMax has established a highly differentiated oncology pipeline addressing large commercial opportunities. At the core of the portfolio is AMB-101, a novel antibody-drug conjugate (ADC) enabled by a proprietary next generation topoisomerase I inhibitor-based linker-payload that has demonstrated a broadened therapeutic index and will enter the clinic in the second half of 2023. AMB-101 targets a tumor associated antigen overexpressed across a broad range of solid tumors and has shown robust efficacy in multiple preclinical models.